Wedbush analyst Laura Chico raised the firm’s price target on Alto Neuroscience (ANRO) to $22 from $13 and keeps a Neutral rating on the shares. Most notable in Q4 results, the company completed a $120M private placement which extends cash runway through 2029. Proceeds will help fund the ALTO-207 Phase 2b study in treatment-resistant depression.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating
- Alto Neuroscience Secures $120 Million Private Placement Financing
- Alto Neuroscience to sell 2.9M shares at $20.00 in private placement
- Alto Neuroscience reports FY25 EPS ($2.19) vs. ($2.50) last year
- Alto Neuroscience sees cash runway into 2028